Ligand Pharmaceuticals (LGND) Capital Expenditures Growth (3y) (2013 - 2026)
Ligand Pharmaceuticals (LGND) Capital Expenditures Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -12.25% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 46.88% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 8.97% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Ligand Pharmaceuticals | 5.92 Bn | 5.14 Bn | 48.45 Mn | -54.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -54.46% |
| Dec 31, 2025 | -75.32% |
| Sep 30, 2025 | 62.74% |
| Jun 30, 2025 | 42.44% |
| Mar 31, 2025 | -64.72% |
| Dec 31, 2024 | -11.00% |
| Sep 30, 2024 | 28.88% |
| Jun 30, 2024 | -33.54% |
| Mar 31, 2024 | -68.64% |
| Dec 31, 2023 | -186.49% |
| Sep 30, 2023 | 206.87% |
| Jun 30, 2023 | -117.00% |
| Mar 31, 2023 | 237.13% |
| Dec 31, 2022 | 77.58% |
| Sep 30, 2022 | -47.70% |
| Jun 30, 2022 | -63.27% |
| Mar 31, 2022 | 153.01% |
| Dec 31, 2021 | 4.58% |
| Sep 30, 2021 | -308.84% |
| Jun 30, 2021 | 176.16% |